GeoVax Labs, Inc. — Q3 2014 Form 10-Q
Reporting period: Three and nine months ended September 30, 2014; financial statements are unaudited. GeoVax is a clinical-stage biotechnology company developing DNA/MVA vaccines, primarily for HIV, with early-stage Ebola vaccine work.
Financial performance and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Grant revenue | $322,086 | $1,004,211 | $659,867 | $2,242,812 |
| Research and development | $425,498 | $879,104 | $1,344,560 | $2,314,291 |
| General and administrative | $411,814 | $316,452 | $1,128,478 | $1,345,179 |
| Operating loss | $515,226 | $191,345 | $1,813,171 | $1,416,658 |
| Net loss | $514,515 | $190,148 | $1,809,970 | $1,413,229 |
| Loss per common share | $0.02 | $0.01 | $0.07 | $0.07 |
- At September 30, cash and cash equivalents were $862,191, down from $2,513,861 at December 31, 2013. Total assets were $1,053,128; working capital was $756,158.
- Operating cash use was $1,616,167 for the first nine months, versus $872,040 in the comparable 2013 period. Investing cash use was $35,503; there were no financing cash proceeds in the period.
- Current liabilities were $170,233. The company reported no long-term debt, committed credit lines, or other committed funding. No gross margin is presented; grant revenue is recognized as qualifying grant-funded costs are incurred.
Changes versus the prior comparable period
- Nine-month grant revenue fell about 71%, primarily reflecting lower grant-supported activity and related expenditures. R&D expense also declined; management attributed the reduction to lower NIH-funded activity and completion of a therapeutic HIV Phase 1 trial.
- Nine-month net loss increased about 28%, while Q3 net loss increased from $190,148 to $514,515. In Q3, lower grant revenue and higher G&A more than offset reduced R&D expense.
- Cash declined by $1,651,670 from year-end 2013. The company received no financing cash in the nine-month period, compared with $1,643,333 in the 2013 period.
Outlook, risks, and unusual items
- Management said available cash and remaining NIH grant support were expected to fund planned operations into 2015, but the filing gives inconsistent timing: one passage says the first quarter and others say the second quarter. Additional capital is needed beyond that runway; management was pursuing grants, clinical-trial support, warrant exercises, and equity offerings, with no assurance funding would be available on acceptable terms.
- The preventive clade B HIV vaccine completed Phase 2a; the next clinical-trial design and NIH/HIV Vaccine Trials Network support remained uncertain. A planned HIV “shock and kill” Phase 1b trial was anticipated in 2015 and expected to cost under $1 million, subject to funding. Ebola preclinical animal studies were expected to begin in 2015, with human testing targeted for 2016.
- GeoVax has no approved products or commercialization capabilities, expects continuing losses, and stated that failure to obtain financing could force it to delay, scale back, or eliminate programs or reduce overhead. Vaccine development, clinical outcomes, regulatory clearance, and grant availability are material uncertainties.
- At September 30, approximately $452,000 of approved NIH grant funds remained available. Lease and firm purchase commitments totaled about $243,000, including approximately $211,000 of unrecorded vendor and subcontractor commitments expected to come due in 2014.
- Subsequent events: in October, warrant exercises for 3,176,000 shares generated $873,400 net of exercise fees; holders also converted preferred shares into 2,928,571 common shares. As of November 11, 31,950,813 common shares were issued and outstanding. The filing also records warrant repricing/extension expense of $39,711 and 250,000 consultant shares issued in July for services valued at $50,000.
- The financial statements report nine-month R&D expense of $1,344,560, but the MD&A narrative gives $2,341,291 for the comparable figure; the reported total operating expenses align with $1,344,560. The filing states there were no material changes to previously disclosed risk factors and no legal proceedings.
Key facts for investors to verify
- Clarify the stated cash runway: first quarter versus second quarter 2015, and assess the financing needed to sustain operations.
- Confirm the correct nine-month 2013 R&D comparative amount given the inconsistency between the financial statements and MD&A narrative.
- Track cash burn, grant availability, and the terms and timing of further financing, including dilution from warrants, preferred conversions, and potential equity offerings.
- Monitor NIH/HVTN support and the design, funding, and timing of the next HIV clinical trials, as well as progress toward the stated Ebola development milestones.